Skip to main content
Top
Published in: Clinical Pharmacokinetics 8/2019

Open Access 01-08-2019 | Clozapine | Original Research Article

Unbound Fraction of Clozapine Significantly Decreases with Elevated Plasma Concentrations of the Inflammatory Acute-Phase Protein Alpha-1-Acid Glycoprotein

Authors: Wai Hong Man, Ingeborg Wilting, Eibert R. Heerdink, Gerard W. K. Hugenholtz, Tim Bognár, Maarten J. ten Berg, Wouter W. van Solinge, Toine A. C. G. Egberts, Erik M. van Maarseveen

Published in: Clinical Pharmacokinetics | Issue 8/2019

Login to get access

Abstract

Background

During inflammation, elevated total (unbound plus protein-bound) clozapine plasma concentrations have been observed. Elevated alpha-1-acid glycoprotein concentrations during inflammation are suggested to cause increased plasma clozapine-alpha-1-acid glycoprotein binding, resulting in elevated total clozapine plasma concentrations without significant changes in unbound concentrations. Here, we investigated the association between alpha-1-acid glycoprotein plasma concentrations and clozapine unbound fraction.

Methods

First, 25 and 60 µL of alpha-1-acid glycoprotein solution (20 mg/mL) were added to plasma samples (n = 3) of clozapine users (spiking experiment). Second, the association between alpha-1-acid glycoprotein plasma concentration and clozapine unbound fraction was assessed in patient samples (patient study). Samples were determined by liquid chromatography-tandem mass spectrometry. Data were analyzed with a paired t test (spiking experiment) and an unpaired t test (patient study).

Results

The spiking experiment showed significantly lower mean unbound fractions following 25- and 60-µL alpha-1-acid glycoprotein spikes (relative reductions of 28.3%, p = 0.032 and 43.4%, p = 0.048). In the patient study, total clozapine plasma concentrations were 10% higher in elevated (n = 6) compared with normal alpha-1-acid glycoprotein (n = 20) samples [525 µg/L vs. 479 µg/L, mean difference = 47 µg/L (95% confidence interval −217 to 310), p = 0.72]. Elevated alpha-1-acid glycoprotein samples had a 26% lower mean unbound fraction compared with normal samples [1.22% vs. 1.65%, mean difference = −0.43% (95% confidence interval −0.816 to −0.0443), p = 0.03].

Conclusions

Both the spiking experiment and patient study showed a significant association between elevated alpha-1-acid glycoprotein plasma concentrations and a lower clozapine unbound fraction. Future studies should include clinical data to examine whether this association is clinically relevant, suggesting any clozapine dose adjustments.
Literature
2.
go back to reference Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed
3.
go back to reference Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.CrossRefPubMed Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.CrossRefPubMed
4.
go back to reference Hefner G, Shams MEE, Unterecker S, Falter T, Hiemke C. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology (Berl). 2016;233:1695–705.CrossRefPubMed Hefner G, Shams MEE, Unterecker S, Falter T, Hiemke C. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology (Berl). 2016;233:1695–705.CrossRefPubMed
5.
go back to reference Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, et al. Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol. 2009;29:392–4.CrossRefPubMed Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, et al. Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol. 2009;29:392–4.CrossRefPubMed
6.
go back to reference ten Bokum EM, van de Oever HLA, Radstake DWS, Arbouw MEL. Clozapine intoxication due to cessation of smoking and infection. Neth J Med. 2015;73:345–7.PubMed ten Bokum EM, van de Oever HLA, Radstake DWS, Arbouw MEL. Clozapine intoxication due to cessation of smoking and infection. Neth J Med. 2015;73:345–7.PubMed
7.
go back to reference Matthews CJ, Hall TL. A clozapine conundrum: clozapine toxicity in an acute medical illness. Australas Psychiatry. 2014;22:543–5.CrossRefPubMed Matthews CJ, Hall TL. A clozapine conundrum: clozapine toxicity in an acute medical illness. Australas Psychiatry. 2014;22:543–5.CrossRefPubMed
8.
go back to reference Takahashi T, Masuya Y, Ueno K, Watanabe K, Takahashi M, Morita S, et al. Clozapine-related negative myoclonus associated with urinary tract infection: a case report. J Clin Psychopharmacol. 2015;35:205–6.CrossRefPubMed Takahashi T, Masuya Y, Ueno K, Watanabe K, Takahashi M, Morita S, et al. Clozapine-related negative myoclonus associated with urinary tract infection: a case report. J Clin Psychopharmacol. 2015;35:205–6.CrossRefPubMed
9.
go back to reference Yadav DS, Singh S. Toxic levels of clozapine in a patient with acute urethritis. Prog Neurol Psychiatry. 2013;17:14–6.CrossRef Yadav DS, Singh S. Toxic levels of clozapine in a patient with acute urethritis. Prog Neurol Psychiatry. 2013;17:14–6.CrossRef
10.
go back to reference Raaska K, Raitasuo V, Arstila M, Neuvonen PJ. Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol. 2002;58:321–2.CrossRefPubMed Raaska K, Raitasuo V, Arstila M, Neuvonen PJ. Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol. 2002;58:321–2.CrossRefPubMed
11.
go back to reference de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1059–63.CrossRefPubMed de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1059–63.CrossRefPubMed
12.
go back to reference Jecel J, Michel TM, Gutknecht L, Schmidt D, Pfuhlmann B, Jabs BE. Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol. 2005;60:909–10.CrossRefPubMed Jecel J, Michel TM, Gutknecht L, Schmidt D, Pfuhlmann B, Jabs BE. Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol. 2005;60:909–10.CrossRefPubMed
13.
go back to reference Haack MJ, Bak MLFJ, Beurskens R, Maes M, Stolk LML, Delespaul PAEG. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol. 2003;13:381–5.CrossRefPubMed Haack MJ, Bak MLFJ, Beurskens R, Maes M, Stolk LML, Delespaul PAEG. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol. 2003;13:381–5.CrossRefPubMed
14.
go back to reference Diaz FJ, de Leon J, Josiassen RC, Cooper TB, Simpson GM. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res. 2005;72:131–5.CrossRefPubMed Diaz FJ, de Leon J, Josiassen RC, Cooper TB, Simpson GM. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res. 2005;72:131–5.CrossRefPubMed
15.
go back to reference Leung JG, Nelson S, Takala CR, Gören JL. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann Pharmacother. 2014;48:801–5.CrossRefPubMed Leung JG, Nelson S, Takala CR, Gören JL. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann Pharmacother. 2014;48:801–5.CrossRefPubMed
16.
go back to reference Sambhi RS, Puri R, Jones G. Interaction of clozapine and ciprofloxacin: a case report. Eur J Clin Pharmacol. 2007;63:895–6.CrossRefPubMed Sambhi RS, Puri R, Jones G. Interaction of clozapine and ciprofloxacin: a case report. Eur J Clin Pharmacol. 2007;63:895–6.CrossRefPubMed
17.
go back to reference Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46:453–9.CrossRefPubMedPubMedCentral Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46:453–9.CrossRefPubMedPubMedCentral
18.
go back to reference Espnes KA, Heimdal KO, Spigset O. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. Ther Drug Monit. 2012;34:489–92.CrossRefPubMed Espnes KA, Heimdal KO, Spigset O. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. Ther Drug Monit. 2012;34:489–92.CrossRefPubMed
19.
go back to reference Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14:25–34.CrossRefPubMed Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14:25–34.CrossRefPubMed
20.
go back to reference Schulte P, Bakker B, Bogers J, Cohen D, van Dijk D. Guideline for the use of clozapine by the Netherlands Clozapine Collaboration Group. 2013; Schulte P, Bakker B, Bogers J, Cohen D, van Dijk D. Guideline for the use of clozapine by the Netherlands Clozapine Collaboration Group. 2013;
21.
go back to reference Hochepied T, Wullaert A, Berger FG, Baumann H, Brouckaert P, Steidler L, et al. Overexpression of α 1-acid glycoprotein in transgenic mice leads to sensitisation to acute colitis. Gut. 2002;51:398–404.CrossRefPubMedPubMedCentral Hochepied T, Wullaert A, Berger FG, Baumann H, Brouckaert P, Steidler L, et al. Overexpression of α 1-acid glycoprotein in transgenic mice leads to sensitisation to acute colitis. Gut. 2002;51:398–404.CrossRefPubMedPubMedCentral
22.
go back to reference European Medicines Agency. Guideline on validation of bioanalytical methods. EMEA/CHMP/EWP/192217/2009. London: Committee for Medicinal Products for Human Use, European Medicines Agency; 2009. European Medicines Agency. Guideline on validation of bioanalytical methods. EMEA/CHMP/EWP/192217/2009. London: Committee for Medicinal Products for Human Use, European Medicines Agency; 2009.
23.
go back to reference Nilsson LB. The bioanalytical challenge of determining unbound concentration and protein binding for drugs. Bioanalysis. 2013;5:3033–50.CrossRefPubMed Nilsson LB. The bioanalytical challenge of determining unbound concentration and protein binding for drugs. Bioanalysis. 2013;5:3033–50.CrossRefPubMed
Metadata
Title
Unbound Fraction of Clozapine Significantly Decreases with Elevated Plasma Concentrations of the Inflammatory Acute-Phase Protein Alpha-1-Acid Glycoprotein
Authors
Wai Hong Man
Ingeborg Wilting
Eibert R. Heerdink
Gerard W. K. Hugenholtz
Tim Bognár
Maarten J. ten Berg
Wouter W. van Solinge
Toine A. C. G. Egberts
Erik M. van Maarseveen
Publication date
01-08-2019
Publisher
Springer International Publishing
Keyword
Clozapine
Published in
Clinical Pharmacokinetics / Issue 8/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-019-00744-6

Other articles of this Issue 8/2019

Clinical Pharmacokinetics 8/2019 Go to the issue